Log in

NASDAQ:FPRX - Five Prime Therapeutics Stock Price, Forecast & News

$4.53
0.00 (0.00 %)
(As of 02/17/2020 08:43 AM ET)
Today's Range
$4.35
Now: $4.53
$4.64
50-Day Range
$4.30
MA: $5.01
$6.04
52-Week Range
$3.18
Now: $4.53
$13.84
Volume357,423 shs
Average Volume371,114 shs
Market Capitalization$164.85 million
P/E RatioN/A
Dividend YieldN/A
Beta2.53
Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FPRX
CUSIPN/A
Phone415-365-5600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$49.87 million
Book Value$7.48 per share

Profitability

Net Income$-140,450,000.00
Net Margins-921.30%

Miscellaneous

Employees209
Market Cap$164.85 million
Next Earnings Date2/27/2020 (Confirmed)
OptionableOptionable

Receive FPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for FPRX and its competitors with MarketBeat's FREE daily newsletter.


Five Prime Therapeutics (NASDAQ:FPRX) Frequently Asked Questions

What is Five Prime Therapeutics' stock symbol?

Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX."

How were Five Prime Therapeutics' earnings last quarter?

Five Prime Therapeutics Inc (NASDAQ:FPRX) released its quarterly earnings data on Wednesday, November, 6th. The biotechnology company reported ($1.03) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.95) by $0.08. The biotechnology company had revenue of $2.98 million for the quarter, compared to analysts' expectations of $4.33 million. Five Prime Therapeutics had a negative net margin of 921.30% and a negative return on equity of 65.39%. View Five Prime Therapeutics' Earnings History.

When is Five Prime Therapeutics' next earnings date?

Five Prime Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Five Prime Therapeutics.

How can I listen to Five Prime Therapeutics' earnings call?

Five Prime Therapeutics will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for FPRX?

4 analysts have issued 1 year target prices for Five Prime Therapeutics' stock. Their forecasts range from $10.00 to $24.00. On average, they expect Five Prime Therapeutics' stock price to reach $14.67 in the next year. This suggests a possible upside of 223.8% from the stock's current price. View Analyst Price Targets for Five Prime Therapeutics.

What is the consensus analysts' recommendation for Five Prime Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Five Prime Therapeutics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Five Prime Therapeutics.

Has Five Prime Therapeutics been receiving favorable news coverage?

Media coverage about FPRX stock has trended somewhat positive this week, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Five Prime Therapeutics earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Five Prime Therapeutics.

Are investors shorting Five Prime Therapeutics?

Five Prime Therapeutics saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 1,710,000 shares, an increase of 14.0% from the January 15th total of 1,500,000 shares. Based on an average daily trading volume, of 488,500 shares, the short-interest ratio is currently 3.5 days. Currently, 4.8% of the company's stock are short sold. View Five Prime Therapeutics' Current Options Chain.

Who are some of Five Prime Therapeutics' key competitors?

What other stocks do shareholders of Five Prime Therapeutics own?

Who are Five Prime Therapeutics' key executives?

Five Prime Therapeutics' management team includes the folowing people:
  • Mr. Aron Marc Knickerbocker, Pres, CEO & Director (Age 50)
  • Mr. Francis W. Sarena, Chief Strategy Officer & Sec. (Age 48)
  • Dr. Helen Louise Collins, Sr. VP & Chief Medical Officer (Age 56)
  • Dr. Peder K. Jensen, Advisor & Director (Age 64)
  • Mr. David V. Smith, Exec. VP & CFO

Who are Five Prime Therapeutics' major shareholders?

Five Prime Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include BVF Inc. IL (21.39%), Renaissance Technologies LLC (4.84%), State Street Corp (1.72%), AQR Capital Management LLC (1.23%), Jacobs Levy Equity Management Inc. (0.99%) and Assenagon Asset Management S.A. (0.76%). Company insiders that own Five Prime Therapeutics stock include Andrew T Feldstein, Bvf Partners L P/Il, Franklin M Berger and Value Fund L P Biotechnology. View Institutional Ownership Trends for Five Prime Therapeutics.

Which major investors are selling Five Prime Therapeutics stock?

FPRX stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., UBS Group AG, State Street Corp, Citigroup Inc., Bank of New York Mellon Corp, Bank of America Corp DE and Charles Schwab Investment Management Inc.. View Insider Buying and Selling for Five Prime Therapeutics.

Which major investors are buying Five Prime Therapeutics stock?

FPRX stock was bought by a variety of institutional investors in the last quarter, including BVF Inc. IL, Renaissance Technologies LLC, AQR Capital Management LLC, Jacobs Levy Equity Management Inc., Acadian Asset Management LLC, Russell Investments Group Ltd., Platinum Investment Management Ltd. and Fred Alger Management LLC. Company insiders that have bought Five Prime Therapeutics stock in the last two years include Andrew T Feldstein, Bvf Partners L P/Il and Value Fund L P Biotechnology. View Insider Buying and Selling for Five Prime Therapeutics.

How do I buy shares of Five Prime Therapeutics?

Shares of FPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Five Prime Therapeutics' stock price today?

One share of FPRX stock can currently be purchased for approximately $4.53.

How big of a company is Five Prime Therapeutics?

Five Prime Therapeutics has a market capitalization of $164.85 million and generates $49.87 million in revenue each year. The biotechnology company earns $-140,450,000.00 in net income (profit) each year or ($4.13) on an earnings per share basis. Five Prime Therapeutics employs 209 workers across the globe.View Additional Information About Five Prime Therapeutics.

What is Five Prime Therapeutics' official website?

The official website for Five Prime Therapeutics is http://www.fiveprime.com/.

How can I contact Five Prime Therapeutics?

Five Prime Therapeutics' mailing address is 111 Oyster Point Boulevard, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 415-365-5600 or via email at [email protected]


MarketBeat Community Rating for Five Prime Therapeutics (NASDAQ FPRX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  287 (Vote Outperform)
Underperform Votes:  231 (Vote Underperform)
Total Votes:  518
MarketBeat's community ratings are surveys of what our community members think about Five Prime Therapeutics and other stocks. Vote "Outperform" if you believe FPRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FPRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Featured Article: Correction

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel